Member Info for HarChris

It's largely unreadable yes because of squabbles between a couple of posters and those attempting to cross ramp other gold explorers over JAN. Annoying.

Personally I think the risk/reward here is fantastic. Two medium sized gold projects with likely close to half a million gold ounces inferred by the end of this year (with the potential for a sizeable uplift) as well as a vanadium project that once, alone, saw JAN valued at well over £25m (during 2022).

And a fall of almost 66% from the recent high of 3p despite very little change fundamentally.

It was 6th June last year, previous year was 21st June.

Suspect it'll be back end of next week or the week after that.

There has been a significant uptick in patients dosed across TNBC/STS over the past six months, from just 8 patients to 21 now.

So up until more recently there just weren't enough patients to draw any conclusions but there is now and we are getting the full release around the time of the BIO International conference.

Far from dropped.

'If there was anything there to interest Pharma wouldn’t it have happened by now'

Deals happen when both parties are in agreement in terms of value, no deals up until now is probably due to Avacta valuing assets and IP far higher than an acquirer / partner was willing to agree to at that stage but perhaps we're close to where agreements come soon / avacta climb down somewhat in order to publicly demonstrate that much needed third party validation / fund 6103 beyond the initial p1a.

We should certainly see far better efficacy (from a tumour shrinkage POV) from the TNBC and STS patients because Dox is more sensitive to those tumours but i'd imagine the results will be mixed and difficult to interpret, especially for TNBC where patients have already been dosed with anthracyclines and therefore previously quickly hit the cumulative Dox limit.

Perhaps management will attempt to separate the data / attempt to highlight the results seen post limit was lifted in February?

If you mean the market isn’t buying it that ATM is currently cash flow positive then that’s bol*ocks, peking, it is as certain as one can be.

The market often doesn’t price in such events because it’s not expecting such elevated commodity prices to last / isn’t convinced that ATM will make the necessary operational upgrades to remain as profitable even if tin prices comes down $10k/t, which is a reasonable assumption.

There might be reasons to be doubtful on other fronts but one can’t genuinely conclude that still at $56.5k ATM might be short of cash flow positivity.

AISC will be a tad higher now because the royalty is a revenue based royalty and tin price is far higher than it was but the margin will still be incredible and unlikely anything we’d ever see at typical tin price even if all the expansions were completed successfully.

Every part of the business is now being developed in the middle of a commodity bull market / potential green transition inspired commodity supercycle.

There’s a clear path to a $1B+ multi metal producer here with half decent execution and a bit of luck along the way.

Well hedge is over and tin is at $56.5k right now, we can without doubt conclude that ATM are seeing meaningful positive cash flow.

Hopefully no more large capex requirements so we can see considerable deleveraging from here on out, supercharged by the Goan supply agreement and / or the ore sorter initiative.

Both have huge potential upside relative to current market caps, both have similar (bit also quite differing) hurdles to overcome to achieve it.

The near term downside threat from the 1p warrants is eliminated down at this price making it very attractive from a trading perspective - suddenly just 1.6p is a 50% rise.

Yeah that's definitely the goal for 6103 and it has effectively shown this in preclinical with those high percentages (often 100%) of complete responses...

The first drug in development going after very challenging heterogenous rare cancer types was never about a cure and everything to do with being a kinder therapy and extending life.

I think Christina said in the most recent interview that we won't hear about any applications like that, we'll just hear when granted.

Teabag Eggy Thornogson posts here to give himself a break from talking up his main investment MATD which constantly lets him down and loses him money.

TD you’re conflating things here.

I’m quite clearly not saying that small caps with strong institutional backing never fail, that would be obviously false and easy to prove like you’ve done listed examples.

I am saying that institutions continuing to buy in / build stakes is a bullish signal, it’s a positive signal.

Does it guarantee success here? Of course not! What if the commodity market suddenly crashes out of the blue? Well then all of us PIs and IIs will do badly and that’s how things go sometimes. BUT IIs still know what they are doing and investment comes with serious due diligence, hence their continual backing shows that they’ve concluded the odds are very good medium term to make a decent return.

I don’t agree, I doubled up my (albeit small) holding today, adding for the first time in a long while.

I still think sentiment will return to the gold space and with it to JAN’s two excellent gold projects. Should be a bright future here with the right tailwind.

Raising as a profitable producer is a totally different situation to raising as an explorer.

If they meet the Maddens production timeline (Q3) all shareholder will do very well from here.

All true but at the end of the day institutions ARE investing and therefore do seem to trust him, unless there's a plan amongst a number of them to push for a new CEO or installing their own. Possible but seems more likely they are invested in the ATM story and therefore we should at least acknowledge that the powerful actors here appear to being seeing through all the delays and missteps and expect eventual success.

I actually think they had around £1.5m in cash in early Q1 and would run out of cash in Q3 if no ounces sold beforehand but that shouldn't be the case.

I doubt they generate enough from Raglan and Maddens this year to cover the AUD$2m in late November however so possibly a small raise beforehand to cover some of that cash payment - if enough progress is made between now and then though raising a few quid whilst being a multiasset producer won't be challenging and will come at a far higher share price.

So what matters most is ounces delivered over the coming five months.

When LDA speaks people listen, so now is the time to be patient.

If this investment fails Nick will have still earnt a few hundred £k , if he makes a major success of it he’ll end up with something like £2m in shares plus will easily command a much higher salary.

Either way he’ll be fine but there’s certainly financial incentive to make a major success of this.

Ps to Bailey, the irony of you saying I need to get out more whilst you write frantic ranty posts multiple times a day for a share you’re not even invested in made me chuckle!